Mark Gergen, Poseida CEO

Roche wades deep­er in­to the al­lo­gene­ic CAR-T field, re­serv­ing bil­lions for its next ear­ly-stage part­ner

Roche has tak­en its next big step in­to the al­lo­gene­ic CAR-T field, this time ty­ing up along­side Po­sei­da Ther­a­peu­tics $PSTX with $220 mil­lion in up­front and quick cash in a trade­mark on­col­o­gy al­liance that comes with a moth­er lode of mile­stones.

The deal — which in­cludes $110 mil­lion for the up­front plus $110 mil­lion in near-term cash — of­fers the phar­ma gi­ant dibs on a slate of off-the-shelf CAR-Ts for hema­to­log­ic ma­lig­nan­cies, in­clud­ing P-BC­MA-AL­LO1 for mul­ti­ple myelo­ma, now in a Phase I study, and P-CD19CD20-AL­LO1, an al­lo­gene­ic dual CAR-T for the treat­ment of B-cell ma­lig­nan­cies with an IND ex­pect­ed in 2023. But they will al­so work on more tar­gets to­geth­er — ham­mer­ing out new re­search tech along the way — as the Po­sei­da team takes the lead on ear­ly-stage tests and Roche carves out re­spon­si­bil­i­ty for the piv­otal plays.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.